The GC-GR-Klf15-BCAA pathway therefore contributes to SMA pathogenesis and could be a potential therapeutic target to alleviate peripheral and metabolic pathologies in SMA. This evidence concerns the gene KLF15 and proximal spinal muscular atrophy.